5/6/2013

Bristol-Myers Squibb and Ambrx agreed to co-develop antibody drug conjugates for cancer with the latter's protein medicinal technology. Ambrx will receive $15 million upfront and as much as $97 million in research funding and milestone fees for each product, plus sales royalties. Bristol will get the global rights to develop and market the drugs arising from the partnership.

Related Summaries